Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3333677 | Seminars in Hematology | 2010 | 7 Pages |
Abstract
Several recent studies have reported the phenomenon of late-onset neutropenia occurring usually several months following the administration of rituximab or rituximab-based therapies. While it appears that late-onset neutropenia is usually not clinically significant and is self-limited, it is important to recognize its existence given the expanding use of rituximab in both hematologic and nonhematologic disorders. Late-onset neutropenia is intriguing biologically and while its pathogenesis and mechanism are not completely understood, many interesting hypotheses have been proposed to explain its occurrence.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Kieron Dunleavy, Kevin Tay, Wyndham H. Wilson,